Jeffrey Whitman, MD
Ophthalmology · Dallas, TXNPI 1669401162
Payments from drug & device makers
Across 893 payments — averaging $1916.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$502K
- Alcon Research LLC$423K
- Rxsight Inc$423K
- AbbVie$124K
- Glaukos Corporation$100K
- Bausch Health US, LLC$85K
- plus $55K from 24 others
Across 7 payments — averaging $8554.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beaver-visitec International, Inc.$54K
- Rxsight Inc$6K
What the payments were for
- Royalty or licence$146,32377%
- Consulting fees$23,77612%
- Speaking & faculty fees$3,4262%
- Travel & lodging$7,3514%
- Food & beverage$9,3105%
- Education$600%
- Gifts$1210%
- Entertainment$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 61 | $502,062 |
| Alcon Research LLC | 368 | $423,294 |
| Rxsight Inc | 148 | $422,945 |
| AbbVie(2 entities) | 37 | $123,546 |
| Glaukos Corporation | 101 | $99,857 |
| Bausch Health US, LLC | 38 | $84,668 |
| Bausch & Lomb Americas Inc. | 24 | $36,309 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $4,915 |
| Alcon | 42 | $2,938 |
| Tarsus Pharmaceuticals, Inc. | 8 | $2,634 |
| Eyepoint US, Inc. | 6 | $2,243 |
| Ivantis, Inc | 6 | $1,540 |
| Lumibird Medical Inc. | 1 | $1,500 |
| Beaver-visitec International, Inc. | 1 | $1,000 |
| Novartis | 14 | $450 |
| NEW World Medical,inc. | 3 | $282 |
| Lensar, Inc. | 1 | $249 |
| Amgen(2 entities) | 4 | $182 |
| Biotissue Holdings Inc. | 3 | $143 |
| Harrow Eye, LLC | 4 | $84 |
| Rayner Intraocular Lenses Limited | 2 | $82 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Sight Sciences, Inc. | 3 | $69 |
| Staar Surgical Company | 1 | $64 |
| Lombart Brothers, Inc. | 1 | $48 |
| Ocular Therapeutix, Inc. | 1 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Oasis Medical, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$146,323
- Tecnis IOL$12,777
- RXSIGHT CONTACT LENS$6,659
- RXSIGHT INJECTOR CARTRIDGE$6,659
- RXSIGHT INJECTOR HANDPIECE$6,659
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$6,659
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$6,509
- Tecnis Simplicity$4,225
- OPHTHALMIC INSTRUMENTS$3,350
- DEXYCU$2,200
- enVista MX60 IOL$2,111
- Tango-R SLT/YAG Combination Laser with Reflex Technology$1,500
- Hydrus$1,156
- enVista Aspire IOL$1,058
- TENEO$1,058
- STELLARIS ELITE$1,058
- Verion$1,000
- Centurion$700
- Wavelight Refractive Suite$651
- Hydrus Microstent$495
How this compares
$1,711,301 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BesivanceBesifloxacin Hcl | 17 | $3,758 |
| Bromfenac Sodium | 16 | $2,336 |
| Prednisolone Acetate | 47 | $1,460 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $799 |
| MoxifloxacinMoxifloxacin Hcl | 20 | $439 |
| Latanoprost | 23 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance | $4,915 | $3,75817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Oluwatosin SmithDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.